

DAFTAR PUSTAKA

- Abd El-Aziz, G. *et al.* (2014) 'Synthesis of human insulin gene in vitro through computational methodology', *Life Science Journal*, 11(1), pp. 1097–8135. Available at: <http://www.lifesciencesite.com><http://www.lifesciencesite.com>.4.
- Abd Rabo, S. *et al.* (2013) 'Serum visfatin in type 2 diabetes mellitus.', *Egypt. J. Intern. Med.*, 25(1), pp. 27–32. doi: 10.7123/01.EJIM.0000425961.54125.23.
- ADA (2021) '2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021', *Diabetes Care*, 44(January), pp. S15–S33.
- Adhau, S., Girish, S. and Kansara, G. (2015) 'Insulin resistance in sub clinical hypothyroidism', *International Journal of Research in Medical Sciences*, 4(9), pp. 1420–1425. doi: 10.18203/2320-6012.ijrms20150159.
- Ahmad, N. *et al.* (2016) 'Abdominal obesity indicators: Waist circumference or waist-to-hip ratio in Malaysian adults population', *International Journal of Preventive Medicine*, 7(1), p. 82. doi: 10.4103/2008-7802.183654.
- Akbarzadeh, S. *et al.* (2012) 'Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus', *Diabetes Research and Clinical Practice*, 95(1), pp. 132–138.
- Al-Musa, H. M. (2017) 'Impact of Obesity on Serum Levels of Thyroid Hormones among Euthyroid Saudi Adults', *Journal of Thyroid Research*, 2017.
- Ansari, S., Haboubi, H. and Haboubi, N. (2020) 'Adult obesity complications: challenges and clinical impact', *Therapeutic Advances in Endocrinology and Metabolism*, 11, p. 204201882093495. doi: 10.1177/2042018820934955.
- Aras, S., Ustunsoy, S. and Armutcu, F. (2015) 'Indices of Central and Peripheral Obesity; Anthropometric Measurements and Laboratory Parameters of Metabolic Syndrome and Thyroid Function', *Balkan Medical Journal*, 32(4), pp. 414–420. doi: 10.5152/balkanmedj.2015.151218.
- Baltacı, D. *et al.* (2016) 'Evaluation of Visfatin in Patients with Obesity, Metabolic Syndrome, Insulin Resistance and Impaired Glucose Tolerance; Case-Control Study', *Acta Medica Anatolia*, 4(2), pp. 61–67. doi: 10.5505/actamedica.2016.00710.
- Bi, T. and Che, X. (2010) 'Namp1/PBEF/visfatin and cancer', *Cancer Biology & Therapy*, 10(2), pp. 119–125. doi: 10.4161/cbt.10.2.12581.
- Bosomworth, N. J. (2019) 'Normal-weight central obesity', *Canadian Family*

Physician, 65, pp. 11–15.

Castro, A. V. B. *et al.* (2014) 'Obesity, insulin resistance and comorbidities? Mechanisms of association', *Arquivos Brasileiros de Endocrinologia & Metabologia*, 58(6), pp. 600–609. doi: 10.1590/0004-2730000003223.

Chang, Y.-H. *et al.* (2014) 'Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review', *Diabetes/Metabolism Research and Reviews*, 27, pp. 515–527. doi: 10.1002/dmrr.

Chen, M.-P. *et al.* (2006) 'Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus', *The Journal of Clinical Endocrinology & Metabolism*, 91(1), pp. 295–299. doi: 10.1210/jc.2005-1475.

Corona-Meraz, F.-I. *et al.* (2020) 'Adipose tissue in health and disease: Adipose Tissue in Health and Disease', *Open Biology*, 10(12). doi: 10.1098/rsob.200291rsob200291.

Cowley, M. A., Brown, W. A. and Considine, R. V. (2015) *Obesity: The Problem and Its Management*. Seventh Ed, *Endocrinology: Adult and Pediatric*. Seventh Ed. Elsevier Inc. doi: 10.1016/B978-0-323-18907-1.00026-3.

Diniz, M. de F. H. S. *et al.* (2020) 'Homeostasis model assessment of insulin resistance (HOMA-IR) and metabolic syndrome at baseline of a multicentric Brazilian cohort: ELSA-Brasil study', *Cadernos de Saúde Pública*, 36(8). doi: 10.1590/0102-311x00072120.

El-Adl, O. S. E.-S. K. M. B. H. I. T. (2012) 'Increased Serum Visfatin Levels in Patients with Type2 Diabetic Patients', 25(64), pp. 187–195.

Esteghamati, A. *et al.* (2011) 'Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity', *Diabetes Research and Clinical Practice*, 91(2), pp. 154–158. doi: 10.1016/j.diabres.2010.11.003.

Esteve Ràfols, M. (2014) 'Adipose tissue: Cell heterogeneity and functional diversity', *Endocrinología y Nutrición (English Edition)*, 61(2), pp. 100–112. doi: 10.1016/j.endoen.2014.02.001.

Flamment, M. *et al.* (2012) 'New insights into ER stress-induced insulin resistance', *Trends in Endocrinology & Metabolism*, 23(8), pp. 381–390. doi: 10.1016/j.tem.2012.06.003.

Flier, J. S. and Maratos-Flier, E. (2018) 'Pathobiology of Obesity', *Harrison's Principles of Internal Medicine*, 20th. ed., pp. 2837–2843.

Fonseca, M. I. H., da Silva, I. T. and Ferreira, S. R. G. (2017) 'Impact of

menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?', *Diabetology & Metabolic Syndrome*, 9(1), p. 22. doi: 10.1186/s13098-017-0221-5.

Fruh, S. M. (2017) 'Obesity', *Journal of the American Association of Nurse Practitioners*, 29(S1), pp. S3–S14. doi: 10.1002/2327-6924.12510.

Fukuhara, A. *et al.* (2005) 'Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin', *Science*, 307(5708), pp. 426–430. doi: 10.1126/science.1097243.

Gadde, K. M. *et al.* (2018) 'Obesity: Pathophysiology and Management', *Journal of the American College of Cardiology*, 71(1), pp. 69–84. doi: 10.1016/j.jacc.2017.11.011.

Gómez, R. *et al.* (2013) 'Visfatin: a new player in rheumatic diseases', *Immunometabolism*, 1(January). doi: 10.2478/immun-2013-0002.

Hall, J. . (2016) *Textbook of Medical Physiology*. Edited by A. Guyton and J. Hall. Philadelphia: Elsevier Saunders.

Han, D.-F. *et al.* (2020) 'An Update on the Emerging Role of Visfatin in the Pathogenesis of Osteoarthritis and Pharmacological Intervention', *Evidence-Based Complementary and Alternative Medicine*, 2020, pp. 1–7. doi: 10.1155/2020/8303570.

Hardy, O. T., Czech, M. P. and Corvera, S. (2012) 'What causes the insulin resistance underlying obesity?', *Curr Opin Endocrinol Diabetes Obes*, 19(2), pp. 81–87. doi: 10.1097/MED.0b013e3283514e13.

Harvey, I., Boudreau, A. and Stephens, J. M. (2020) 'Adipose tissue in health and disease: Adipose Tissue in Health and Disease', *Open Biology*, 10(12). doi: 10.1098/rsob.200291rsob200291.

Heo, Y. J. *et al.* (2019) 'Visfatin Induces Inflammation and Insulin Resistance via the NF- κ B and STAT3 Signaling Pathways in Hepatocytes', *Journal of Diabetes Research*, 2019, pp. 1–11. doi: 10.1155/2019/4021623.

Hetta, H. F. *et al.* (2018) 'Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance', *The Egyptian journal of immunology*, 25(2), pp. 141–151.

Heymsfield, S. B. and Wadden, T. A. (2017) 'Mechanisms, Pathophysiology, and Management of Obesity', *New England Journal of Medicine*. Edited by D. L. Longo, 376(3), pp. 254–266. doi: 10.1056/NEJMra1514009.

Horiba (2006) 'Glucose HK-CP', in *Diagnostic Reagent for Quantitative In Vitro Determination of Glucose*. Horiba.

- Ihsan, I., Rini, E. A. and Yaswir, R. (2017) 'Visfatin levels in non-obese, obese, and insulin resistant adolescents', *Paediatrica Indonesiana*, 56(5), p. 291. doi: 10.14238/pi56.5.2016.291-6.
- Imad, B. (2016) 'The Relationship between Plasma Visfatin/Nampt and Type 2 Diabetes, Obesity, Insulin Resistance, and Cardiovascular Disease', *Endocrinology&Metabolism International Journal*, 3(6), pp. 157–163. doi: 10.15406/emij.2016.03.00068.
- Jung, U. and Choi, M.-S. (2014) 'Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease', *International Journal of Molecular Sciences*, 15(4), pp. 6184–6223. doi: 10.3390/ijms15046184.
- Jurdana, M. *et al.* (2013) 'Increased serum visfatin levels in obesity and its association with anthropometric/biochemical parameters, physical inactivity and nutrition', *e-SPEN Journal*, 8(2), pp. e59–e67. doi: 10.1016/j.clnme.2013.02.001.
- El Kabbaoui, M. *et al.* (2018) 'Prevalence of and risk factors for overweight and obesity among adolescents in Morocco', *Eastern Mediterranean Health Journal*, 24(6), pp. 512–521. doi: 10.26719/2018.24.6.512.
- Kabir, F., Haque, S. A. and Haque, K. (2018) 'Serum Visfatin Levels Estimated in Overweight Individuals', *Anwer Khan Modern Medical College Journal*, 9(2), pp. 91–95. doi: 10.3329/akmmcj.v9i2.39201.
- Kamińska, A. *et al.* (2010) 'An evaluation of visfatin levels in obese subjects', *Endokrynologia Polska*, 61(2), pp. 169–173.
- Katib, A. (2015) 'Mechanisms linking obesity with male infertility', *Central European Journal of Urology*, 68(1), pp. 79–85. doi: 10.5173/cej.2015.01.435.
- Kemenkes RI (2019) 'Hasil Riset Kesehatan Dasar Tahun 2018', *Kementrian Kesehatan RI*, 53(9), pp. 1689–1699.
- Kinlen, D., Cody, D. and O'Shea, D. (2018) 'Complications of obesity', *QJM: An International Journal of Medicine*, 111(7), pp. 437–443. doi: 10.1093/qjmed/hcx152.
- Klein, S. and Romijn, J. . (2016) *Williams Textbook of Endocrinology*. 13th edn. Edited by S. Melmed *et al.* Philadelphia: Elsevier.
- Kumar, V. (2018) 'Environmental and Nutritional Disease', in Kumar, V., Abbas, A. K., and Aster, J. . (eds) *Robbins Basic Pathology*. 10th edn. Philadelphia:

Elsevier.

Kurniawan, L. *et al.* (2018) 'Body Mass, Total Body Fat Percentage, and Visceral Fat Level Predict Insulin Resistance Better Than Waist Circumference and Body Mass Index in Healthy Young Male Adults in Indonesia', *Journal of Clinical Medicine*, 7(5), p. 96. doi: 10.3390/jcm7050096.

Kurniawan, L. B. *et al.* (2020) 'Anthropometric features in predicting insulin resistance among non-menopausal Indonesian adult females', *Romanian Journal of Internal Medicine*, 58(3), pp. 168–172. doi: 10.2478/rjim-2020-0015.

Lim, L. L.-Y. *et al.* (2012) 'Validity of self-reported abdominal obesity in Thai adults: A comparison of waist circumference, waist-to-hip ratio and waist-to-stature ratio', *Nutrition, Metabolism and Cardiovascular Diseases*, 22(1), pp. 42–49. doi: 10.1016/j.numecd.2010.04.003.

Longo, M. *et al.* (2019) 'Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications', *International Journal of Molecular Sciences*, 20(9), p. 2358. doi: 10.3390/ijms20092358.

Lou, M. *et al.* (2015) 'Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients', *BMC Endocrine Disorders*, 15(1), p. 9. doi: 10.1186/s12902-015-0002-9.

Luk, T., Malam, Z. and Marshall, J. C. (2008) 'Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity', *Journal of Leukocyte Biology*, 83(4), pp. 804–816. doi: 10.1189/jlb.0807581.

Malmed, S. (2016) *Williams Textbook of Endocrinology*. 13th edn. Edited by S. Melmed *et al.* Philadelphia: Elsevier.

Manaf, A. (2014) 'Insulin: Mekanisme Sekresi dan Aspek Metabolisme', in Sudoyo, A. W. *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. 6th edn. Jakarta: Interna Publishing, pp. 2350–2354.

Matthews, D. R. *et al.* (1985) 'Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man', *Diabetologia*, 28(7), pp. 412–419. doi: 10.1007/BF00280883.

Mayi, T. H. *et al.* (2010) 'Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages', *FEBS Journal*, 277(16), pp. 3308–3320. doi: 10.1111/j.1742-4658.2010.07729.x.

Millar, S. R. *et al.* (2015) 'Optimal Central Obesity Measurement Site for Assessing Cardiometabolic and Type 2 Diabetes Risk in Middle-Aged Adults', *PLOS ONE*. Edited by Y. Böttcher, 10(6), p. e0129088. doi:

10.1371/journal.pone.0129088.

Moschen, A. R. *et al.* (2007) 'Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties', *The Journal of Immunology*, 178(3), pp. 1748–1758. doi: 10.4049/jimmunol.178.3.1748.

Newsholme, P. *et al.* (2014) 'Nutrient regulation of insulin secretion and action', *Journal of Endocrinology*, 221(3), pp. R105–R120. doi: 10.1530/JOE-13-0616.

Nourbakhsh, Mitra *et al.* (2015) 'Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome', *Scandinavian Journal of Clinical and Laboratory Investigation*, 75(2), pp. 183–188. doi: 10.3109/00365513.2014.1003594.

Olinto, M. T. A., Theodoro, H. and Canuto, R. (2017) 'Epidemiology of Abdominal Obesity', in *Adiposity - Epidemiology and Treatment Modalities*. InTech. doi: 10.5772/65342.

Osama, H. (2017) *Obesity, Emedicine Medscape*. Available at: <http://emedicine.medscape.com/article/123702>.

Ozer Cakir, O. and Yildiz, M. (2016) 'Visceral Fat Volume is a Better Predictor for Insulin Resistance than Abdominal Wall Fat Index in Patients with Prediabetes and Type 2 Diabetes Mellitus', *Internal Medicine: Open Access*, 6(3). doi: 10.4172/2165-8048.1000220.

PERKENI (2018) *Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia, Perkeni*.

Petersen, M. C. and Shulman, G. I. (2018) 'Mechanisms of Insulin Action and Insulin Resistance', *Physiological Reviews*, 98(4), pp. 2133–2223. doi: 10.1152/physrev.00063.2017.

Qatanani, M. and Lazar, M. A. (2010) 'Mechanisms of obesity-associated insulin resistance: many choices on the menu', *Genes & Development*, 21(12), pp. 1443–1455. doi: 10.1101/gad.1550907.

Qu, H.-Q. *et al.* (2011) 'The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican Descent Using Machine Learning', *PLoS ONE*. Edited by A. Vella, 6(6), p. e21041. doi: 10.1371/journal.pone.0021041.

Roche (2013) *Insulin*. Indianapolis: Roche Diagnostic.

Romacho, T., Sánchez-Ferrer, C. F. and Peiró, C. (2013) 'Visfatin/Nampt: An Adipokine with Cardiovascular Impact', *Mediators of Inflammation*, 2013(Cv), pp. 1–15. doi: 10.1155/2013/946427.

Sah, S. P. *et al.* (2016) 'Animal models of insulin resistance: A review',

Pharmacological Reports, 68(6), pp. 1165–1177. doi: 10.1016/j.pharep.2016.07.010.

El Samahi, M. H. *et al.* (2017) 'Study of Visfatin Level in Type 1 Diabetic Children and Adolescents', *Open Access Macedonian Journal of Medical Sciences*, 5(3), pp. 299–304. doi: 10.3889/oamjms.2017.065.

Segula, D. (2014) 'Cmplations of obesity in adults: A short review of the literature', *Malawi Medical Journal*, 26(1), pp. 20–24. doi: 10.4314/MMJ.V26I1.

Shah, N. R. and Braverman, E. R. (2012) 'Measuring adiposity in patients: The utility of body mass index (BMI), percent body fat, and leptin', *PLoS ONE*, 7(4). doi: 10.1371/journal.pone.0033308.

Sherwood, L. (2016) *Human Physiology From Cell to System*. 9th edn. Boston: Cengage Learning.

Sheta, Y. S., Elgohary, E.-S. A. and Sharaf, S. (2012) 'Visfatin Between Fact and Fiction; a Marker of Obesity or a New Player in the Pathogenesis of Type 2 Diabetes Mellitus', *Journal of Asian Scientific Research*, 2(12), pp. 949–957. Available at: <http://aessweb.com/journal-detail.php?id=5003>.

Simões, N. F. *et al.* (2018) 'Resistin and visfatin concentrations are related to central obesity and inflammation in Brazilian children', *Nutrrire*, 43(1), p. 1. doi: 10.1186/s41110-018-0060-7.

Skyler, J. S. *et al.* (2017) 'Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis', *Diabetes*, 66(2), pp. 241–255. doi: 10.2337/db16-0806.

Song, Y. S. *et al.* (2016) 'Comparison of the Usefulness of the Updated Homeostasis Model Assessment (HOMA2) with the Original HOMA1 in the Prediction of Type 2 Diabetes Mellitus in Koreans', *Diabetes & Metabolism Journal*, 40(4), p. 318. doi: 10.4093/dmj.2016.40.4.318.

Stastny, J., Bienertova-Vasku, J. and Vasku, A. (2012) 'Visfatin and its role in obesity development', *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 6(2), pp. 120–124. doi: 10.1016/j.dsx.2012.08.011.

Sugondo, S. (2014) 'Obesitas', in Sudoyo, A. W. *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. 6th edn. Jakarta: Interna Publishing, pp. 1973–1983.



Sultan, D., P., S. and F.A., E. (2013) 'HDL, apo B/apo A1 ratio, Diabetes Mellitus and Cardiovascular Disease', in *Type 2 Diabetes*. InTech. doi: 10.5772/56476.

Susantiningih, T. (2015) 'Obesitas dan Stes Oksidatif', *Jurnal Kedokteran Universitas Lampung*, 5(9), pp. 89–93. doi: 10.1109/ICM.2011.379.

- Tamez-Pérez, H. E. (2015) 'Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review', *World Journal of Diabetes*, 6(8), p. 1073. doi: 10.4239/wjd.v6.i8.1073.
- Tang, Q. *et al.* (2015) 'Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future', *Drug Discoveries & Therapeutics*, 9(6), pp. 380–385. doi: 10.5582/ddt.2015.01207.
- Tchernof, A. and Després, J.-P. (2013) 'Pathophysiology of Human Visceral Obesity: An Update', *Physiological Reviews*, 93(1), pp. 359–404. doi: 10.1152/physrev.00033.2011.
- Walker, G. E. *et al.* (2014) 'The pathophysiology of abdominal adipose tissue depots in health and disease', *Hormone Molecular Biology and Clinical Investigation*, 19(1), pp. 57–74. doi: 10.1515/hmbci-2014-0023.
- World Health Organisation (WHO) (2000) *The Asia – Pacific perspective: redefining obesity and its treatment*. Edited by International Association for the Study of Obesity. International Association for the Study of Obesity.
- World Health Organisation (WHO) (2008) 'WHO | Waist Circumference and Waist–Hip Ratio. Report of a WHO Expert Consultation. Geneva, 8-11 December 2008.', (December), pp. 8–11. Available at: <http://www.who.int>.
- World Health Organisation (WHO) (2020) *Obesity and Overweight*, Springer Reference. Available at: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (Accessed: 5 April 2021).
- Ye, J. (2013) 'Mechanisms of insulin resistance in obesity', *Frontiers of Medicine*, 7(1), pp. 14–24. doi: 10.1007/s11684-013-0262-6.
- Yoon, M. J. *et al.* (2017) 'SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD⁺ and function in mice', *Physiology & Behavior*, 176(5), pp. 139–148. doi: 10.1016/j.physbeh.2017.03.040.
- Yu, C. *et al.* (2015) 'Major Dietary Patterns in Relation to General and Central Obesity among Chinese Adults', *Nutrients*, 7(7), pp. 5834–5849.
- Yu, S. *et al.* (2019) 'Prevalence of Obesity and Associated Risk Factors and Cardiometabolic Comorbidities in Rural Northeast China Shiwen', *BioMed Research International*, 19(1), pp. 1–9. Available at: <https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-019-1202-4>.
- Zhang, Y. *et al.* (2014) 'Obesity: Pathophysiology and Intervention', *Nutrients*, 6(11), pp. 5153–5183. doi: 10.3390/nu6115153.

LAMPIRAN

Lampiran 1. Persetujuan Etik

 <p style="text-align: center;">KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN KESEHATAN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari.,M.Med.,Ph.D., Sp.GK TELP. 081241850858, 0411 5780103, Fax : 0411-581431</p> 			
<p>REKOMENDASI PERSETUJUAN ETIK Nomor : 563/UN4.6.4.5.31/ PP36/ 2021 Tanggal: 6 September 2021</p>			
<p>Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :</p>			
No Protokol	UH21060408	No Sponsor	
Peneliti Utama	dr. Yunita Rapa	Protokol	
Judul Peneliti	Analisis Kadar Visfatin dan Homeostatic Model Assessment - Insulin Resistance (HOMA-IR) Pada Subyek Non Diabetes dengan dan tanpa Obesitas Sentral		
No Versi Protokol	2	Tanggal Versi	3 September 2021
No Versi PSP	2	Tanggal Versi	3 September 2021
Tempat Penelitian	RS Universitas Hasanuddin, Fakultas Kedokteran UNHAS dan Laboratorium Parahita Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	
<p>Kewajiban Peneliti Utama:</p> <ul style="list-style-type: none"> Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah Menyerahkan laporan akhir setelah Penelitian berakhir Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation) Mematuhi semua peraturan yang ditentukan 			

Lampiran 2. Naskah Penjelasan Untuk Mendapat Persetujuan dari Subyek Penelitian

Judul penelitian: Analisis Kadar Visfatin dan Homeostatic Model-Insulin Resistance (HOMA-IR) Pada Subyek Non Diabetes dengan dan tanpa Obesitas Sentral

Penjelasan kepada subyek penelitian:

Selamat pagi Bapak / Ibu / saudara (i), kami dokter yang akan melakukan penelitian mengenai hubungan salah satu komponen didalam sel darah merah kita yaitu Visfatin pada Obesitas (kelebihan berat badan) dan pada pasien dengan berat badan normal. Kriteria overweight (kelebihan berat badan) dan obesitas ditetapkan oleh dokter dengan melakukan pengukuran lingkaran pinggang, pengukuran berat badan dan tinggi badan. Kemudian kami akan menghitung Indeks Massa Tubuh pasien dan akan memberitahukan berapa seharusnya berat badan yang ideal sesuai dengan tinggi badan pasien. Kadar visfatin dalam darah sendiri dikaitkan dengan resistensi (gangguan fungsi) hormon insulin dalam mengatur kadar gula darah dalam tubuh seseorang, sehingga kadar visfatin dalam darah berhubungan dengan komplikasi obesitas (kelebihan berat badan) di masa yang akan datang. Kami akan melakukan pengukuran gula darah puasa dan kadar visfatin, namun pengambilan darah yang kami lakukan hanya satu kali dengan mengikuti prosedur pengambilan darah yang sesuai, yaitu dengan menggunakan jarum yang baru dan menempelkan identitas pasien pada sampel darah. Besar harapan kami agar penelitian ini dapat memberikan sumbangan ilmu pengetahuan dalam upaya mengetahui berat badan yang ideal dan risiko penyakit di masa yang akan datang akibat berat badan yang berlebihan pada Bapak / Ibu / saudara (i) alami.

Adapun penelitian ini tidak memaksa keikutsertaan Bapak / Ibu / saudara (i) dan jika Bapak / Ibu / saudara (i) bersedia menandatangani formulir kesediaan ikut serta dalam penelitian dengan sukarela. Bapak / Ibu / saudara (i) tidak perlu khawatir

ketidaksertaan anda dalam penelitian ini tidak mengurangi pelayanan kesehatan yang akan diperoleh dari pihak rumah sakit.

Bila Bapak/Ibu bersedia untuk menjadi responden dalam penelitian ini, maka prosedur yang kami lakukan adalah mengumpulkan sampel darah vena yang telah diambil (minimal 3 cc) untuk keperluan pemeriksaan laboratorium. Selain pengambilan darah tidak ada tindakan invasif lain yang kami lakukan sehingga kami jamin tidak ada efek samping yang timbul dalam penelitian ini. Kami juga akan melakukan pengukuran berat badan, tinggi badan, lemak tubuh dengan menggunakan timbangan digital dan mengukur lingkar perut dan lengan bagian atas dengan menggunakan meteran.

Dalam penelitian ini kami tidak memberikan kompensasi akan tetapi kami akan memberitahu hasil pengukuran berat badan, tinggi badan, jumlah lemak tubuh Bapak/Ibu / Saudara (i). Segala biaya tambahan dalam pemeriksaan ini sepenuhnya akan ditanggung oleh pihak peneliti sehingga Bapak / Ibu / saudara (i) tidak perlu khawatir.

Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman, sehingga hanya bisa dilihat oleh yang berkepentingan saja. Data pribadi disamarkan pada semua catatan dan pada pelaporan baik lisan ataupun tertulis tidak akan menggunakan data pribadi.

Bila bapak/ibu merasa masih ada hal yang belum jelas atau belum dimengerti dengan baik, maka ibu dapat menanyakan atau minta penjelasan pada kami dr. Yunita Rapa (082148740588).

Penanggung jawab Penelitian

Nama : dr. Yunita Rapa

Alamat : Jalan Kemuliaan Bangkala No. 108 BTP, Makassar

Telepon : 082148740588

Lampiran 4. Data Penelitian

No.	Jenis Kelamin	Umur (Tahun)	Lingkar Pinggang (cm)	GDP (mg/dL)	Visfatin (ng/mL)	Insulin Puasa (μ U/mL)	HOMA-IR
1	LK	37	106	84,8	4,79	8.77	1,84
2	LK	33	95	88,5	7,05	15.02	3,28
3	LK	35	96	83,4	5,18	7,88	1,62
4	LK	26	136,5	75,2	8,11	35.59	6,61
5	LK	27	107.5	97,9	7,91	26.02	6,29
6	LK	27	102	99,1	6,69	14,19	3,47
7	LK	36	105	86,6	5,31	17,61	3,77
8	LK	39	90	89,5	7,15	12,65	2,8
9	LK	30	93,5	112,8	6,55	60,21	16,77
10	LK	33	98	88,7	7,08	14,89	3,26
11	LK	38	97	112,0	6,4	24,44	6,76
12	LK	32	99,5	103,2	5,98	16,55	4,22
13	LK	29	98	94,0	7,2	32,29	7,49
14	LK	22	122	95,2	6,47	15,99	3,76
15	LK	31	99	89,4	10,76	10,97	2,42
16	LK	30	100,5	93,6	7,66	36,62	8,46
17	LK	31	99	102,2	9,76	36,02	9,09
18	LK	28	110	83,0	6,41	14,81	3,04
19	LK	23	93	86,5	8,91	9,7	2,07
20	LK	36	100	79,3	8,61	8,25	1,62
21	LK	30	101,5	84,4	9,6	11,09	2,31
22	PR	35	107	94,5	7,55	18.56	4,33
23	PR	34	100	109,3	6,72	20,9	5,64
24	PR	32	91	92,8	5,65	12,99	2,98
25	PR	38	85	88,9	6,65	10,32	2,27
26	PR	33	81,5	72,7	6,5	8,31	1,49
27	PR	35	89	87,8	7,08	11,7	2,54
28	PR	29	94,5	90,2	6,3	10,75	2,39
29	PR	39	88	88,7	6,17	10,86	2,38
30	PR	35	83	93,9	6,77	11,55	2,68
31	PR	39	87	105,9	8,42	33,82	8,84
32	PR	32	97	119,8	5,98	11,77	3,48
33	PR	31	84	94,4	6,08	9,01	2,1
34	PR	23	92	98,3	5,8	17,11	4,15
35	PR	37	97	89,0	5,72	10,77	2,37
36	PR	33	88	96,2	6,1	13,88	3,3
37	PR	23	85	81,4	4,51	8,85	1,78
38	PR	20	83	82,5	7,39	12,63	2,57
39	PR	35	82	74,7	15,11	19,21	3,54
40	PR	23	80	81,4	6,7	11,76	2,36

No.	Jenis Kelamin	Umur (Tahun)	Lingkar Pinggang (cm)	GDP (mg/dL)	Visfatin (ng/mL)	Insulin Puasa (μ U/mL)	HOMA-IR
41	PR	29	96,5	95,4	9,62	21,23	5
42	PR	34	83	104,5	5,41	11,27	2,91
43	PR	34	83	87,8	7,52	47,15	10,22
44	PR	32	80	84,8	5,08	12,5	2,62
45	LK	33	79	98,2	5,59	8,54	2,07
46	LK	30	84,5	84,7	5,93	10,27	2,15
47	LK	30	81	88,7	5,48	10,04	2,2
48	LK	27	88	78,9	5,71	4,73	0,92
49	LK	31	80	87,2	6,7	4,61	0,99
50	LK	38	77	76,5	7,06	2,59	0,49
51	LK	29	77	88,5	7,73	6,48	1,42
52	LK	33	85	85,1	7,89	4,27	0,9
53	LK	27	73,5	71,5	6,82	17,48	3,09
54	LK	29	71	90,9	5,91	2,61	0,59
55	LK	33	88	95,7	6,51	8,82	2,08
56	LK	23	81	89,1	5,61	11,16	2,46
57	LK	25	80	82,6	6,34	5,85	1,19
58	LK	24	87	81,1	5,33	9,35	1,87
59	LK	22	83	80,3	6,68	7,79	1,54
60	LK	25	83	93,7	7,74	32,92	7,62
61	LK	24	83	83,3	5,52	4,7	0,97
62	LK	31	88	91,2	5,99	23,14	5,21
63	LK	29	82	86,9	7,7	7,09	1,52
64	LK	32	82	91,5	2,52	14,44	3,26
65	LK	25	88	88,9	5,23	9,29	2,04
66	LK	29	88	78	5,42	7,46	1,44
67	PR	28	74	82,2	5,6	12,63	2,56
68	PR	31	77	85,5	5,27	6,92	1,46
69	PR	29	78	81,3	6,24	4,73	0,95
70	PR	33	68	69,3	5,71	11,04	1,89
71	PR	29	71	89,8	4,66	13,15	2,92
72	PR	27	73	88,6	5,37	9,89	2,16
73	PR	27	71	92,4	6,18	7,65	1,75
74	PR	34	73	81,5	4,92	11,36	2,29
75	PR	24	77	80,6	3,23	8,99	1,79
76	PR	33	68	97,1	3,5	5,66	1,36
77	PR	25	75	94,4	5,28	22,24	5,18
78	PR	34	68	90,5	5,72	3,98	0,89
79	PR	28	73	85,6	4,75	8,09	1,71
80	PR	25	73	80,5	5,47	5,12	1,02
81	PR	36	69	88	3,77	12,19	2,65
82	PR	31	79	79,6	5,29	3,99	0,78

Lampiran 5. Curriculum Vitae

DATA PRIBADI

Nama : dr. Yunita Rapa
Tempat, tanggal lahir : Samarinda, 9 Juni 1988
Agama : Kristen Protestan
Pekerjaan : Mahasiswa PPDS
NIP : -
Pangkat/Golongan : -
Alamat : Jalan Kemuliaan Bangkala No. 108 BTP, Makassar

RIWAYAT PENDIDIKAN

NO.	STRATA	INSTITUSI	TEMPAT	TAHUN TAMAT
1	SD	SDN 057	Samarinda	2000
2	SMP	SLTP Negeri 2	Samarinda	2003
3	SMA	SMU Negeri 1	Samarinda	2006
4.	Dokter	Fakultas Kedokteran Univ. Mulawarman	Samarinda	2013
5	Spesialis (sementara)	Bagian Patologi Klinik FK-UNHAS	Makassar	Sekarang

RIWAYAT PEKERJAAN

No	Kedudukan	Instansi	Tempat	Periode
1	Dokter Umum PTT	Dinas Kesehatan Kota Samarinda	UPT. Puskesmas Sambutan, Samarinda	2013-2015
2	Dokter Umum	-	Klinik Aminah Amin, Samarinda	2015-2017